P2-076 - Risk of colorectal cancer in inflammatory bowel disease in Taiwan population

Abstract

Background: Recently, several studies evaluated risk of colorectal cancer (CRC) in ulcerative colitis (UC) and Crohn's disease (CD) patients. Otherwise, a numbers of meta-analysis and systemic review have indicated inflammatory bowel disease (IBD) have high risk to cause colorectal cancer. The purposes of this study are intended to evaluate epidemiology and risks of CRC in IBD patients. Otherwise, we also evaluated correlation between 5-Aminosalicylic acid (5-ASA) and CRC.Methods: This is a retrospective population database research which was identified IBD (ICD-9: 555 and 556) cases from Nation Health Insurance Research Database (NHIRD), 1999-2013. We incurred newly diagnosed IBD patients without CRC patients from 1999 to 2013. We divided our population into three group: 5-ASA users, 5-ASA users combined with other medication, and no exposure. Besides, we evaluated the incident rate of CRC in UC and CD patients. Cox proportional hazard model was used to estimate hazard ratios (HR) of CRC among three group.Results: A total of 215 colorectal cancers were observed in patients with UC (n = 105) and CD (n = 115). The incident rate of UC and CD were 4.3 and 5.4 per 103 person-years, respectively. The average age at diagnosis CRC in IBD patients were 54.3 years. Moreover, the mean duration of IBD before the development of CRC was 30.3 months. Otherwise, patients received 5-ASA compared with no exposure had lower risk of CRC (HRs ranged from 0.75 to 0.89). However, we did not observe the significantly difference between 5-ASA users and 5-ASA users combined with other medication.Conclusion: Our study found that clinical epidemiology of CRC with IBD patients had similar trend with other countries. The IBD-associated CRC have increased in Asian countries. Furthermore, patients treated with 5-ASA had a lower risk for occurrence of CRC in IBD patients. Background: Recently, several studies evaluated risk of colorectal cancer (CRC) in ulcerative colitis (UC) and Crohn's disease (CD) patients. Otherwise, a numbers of meta-analysis and systemic review have indicated inflammatory bowel disease (IBD) have high risk to cause colorectal cancer. The purposes of this study are intended to evaluate epidemiology and risks of CRC in IBD patients. Otherwise, we also evaluated correlation between 5-Aminosalicylic acid (5-ASA) and CRC. Methods: This is a retrospective population database research which was identified IBD (ICD-9: 555 and 556) cases from Nation Health Insurance Research Database (NHIRD), 1999-2013. We incurred newly diagnosed IBD patients without CRC patients from 1999 to 2013. We divided our population into three group: 5-ASA users, 5-ASA users combined with other medication, and no exposure. Besides, we evaluated the incident rate of CRC in UC and CD patients. Cox proportional hazard model was used to estimate hazard ratios (HR) of CRC among three group. Results: A total of 215 colorectal cancers were observed in patients with UC (n = 105) and CD (n = 115). The incident rate of UC and CD were 4.3 and 5.4 per 103 person-years, respectively. The average age at diagnosis CRC in IBD patients were 54.3 years. Moreover, the mean duration of IBD before the development of CRC was 30.3 months. Otherwise, patients received 5-ASA compared with no exposure had lower risk of CRC (HRs ranged from 0.75 to 0.89). However, we did not observe the significantly difference between 5-ASA users and 5-ASA users combined with other medication. Conclusion: Our study found that clinical epidemiology of CRC with IBD patients had similar trend with other countries. The IBD-associated CRC have increased in Asian countries. Furthermore, patients treated with 5-ASA had a lower risk for occurrence of CRC in IBD patients.